恩替卡韦联合双歧杆菌乳杆菌三联活菌片治疗失代偿期乙型肝炎肝硬化临床疗效观察

doi:10.3969/j.issn.1672-5069.2018.05.004

摘要/Abstract

摘要： 目的探讨恩替卡韦联合双歧杆菌乳杆菌三联活菌片治疗失代偿期乙型肝炎肝硬化患者的临床疗效。方法 2015年3月~2017年8月我院收治的120例失代偿期乙型肝炎肝硬化患者被随机分为对照组60例和观察组60例,分别给予恩替卡韦分散片或恩替卡韦联合双歧杆菌乳杆菌三联活菌片治疗,观察24 w。结果在治疗12 w时,观察组血清TBIL为（16.3±4.2） μmol/L,显著低于对照组的（26.3±5.2） μmol/L（P<0.05）,观察组血清ALB为（32.5±4.2）g/L,显著高于对照组的（30.2±5.3） g/L（P<0.05）;在治疗24 w时,观察组血清ALB为（37.8±2.3） g/L,显著高于对照组的（34.4±4.2） g/L（P<0.05）;观察组血清LN和C- IV分别为（65.2±15.1）ng/ml和（85.5±8.5） ng/ml,显著低于对照组的【（75.3±10.3） ng/ml和（96.2±10.3） ng/ml,P<0.05】;观察组血清HBV DNA水平为（1.0±0.1） lg copies/ml,与对照组的（1.7±0.3） lg copies/ml比,无显著性差异（P>0.05）,血清HBV DNA转阴率为100.0%,与对照组的90.0%比,无显著性差异（P>0.05）;在治疗12 w和24 w,观察组发生自发性细菌性腹膜炎（SBP）5例（8.3%）和2例（3.3%）,显著低于对照组的10例（16.7%）和8例（13.3%,P<0.05）;在治疗24 w末,观察组死亡3例（5%）,而对照组死亡10例（16.7%,P<0.05）。结论恩替卡韦联合双歧杆菌乳杆菌三联活菌治疗失代偿期乙型肝炎肝硬化患者能短期改善肝功能指标,降低血清肝纤维化指标水平,减少并发症的发生。

关键词: 肝硬化, 乙型肝炎, 恩替卡韦, 双歧杆菌乳杆菌三联活菌, 治疗

Abstract: Objective To investigate the clinical efficacy of entecavir combined with live bifidobacterium and lactobacillus tablets in the treatment of B patients with decompensated liver cirrhosis. Methods 120 patients with hepatitis B induced decompensated liver cirrhosis in the Affiliated Hospital of the Southwest Medical University between Jan. 2015 and Aug. 2017 were randomly divided into control and observation groups. The patients in the control group were administrated entecavir and patients in the observation group were administrated entecavir and live bifidobacterium and lactobacillus tablets. The index of liver function,hepatic fibrosis,HBV DNA and the rate of spontaneous bacterial peritonitis were compared between the two groups. Results At the end of 12 weeks,serum levels of ALT and TBIL in combination treatment group were（70.2±6.2） U/L and（16.3±4.2） μmol/L,both significantly lower than （76.2±9.6） U/L and （26.3±5.2） μmol/L in the control group（P<0.05）;serum level of ALB in the treatment group was （32.5±4.2） g/L,significantly higher than（30.2±5.3）g/L in the control group（P<0.05）;at the end of 24 weeks,serum levels of ALT and TBIL in the treatment group were （12.2±3.2） U/L and（6.2±1.3） μmol/L,both significantly lower than （26.4±3.2）U/L and （11.2±3.2） μmol/L in the control group （P<0.05）;serum level of ALB in the treatment group was （37.8±2.3） g/L,significantly higher than （34.4±4.2） g/L in the control group （P<0.05）;serum LN and C- IV were （65.2±15.1）ng/ml and （85.5±8.5）ng/ml,much lower than【（75.3±10.3）ng/ml and （96.2±10.3）ng/ml in the control,respectively,P<0.05】;serum HBV DNA level was （1.0±0.1）lg copies/ml,no significantly different as compared to （1.7±0.3） lg copies/ml in the control （P>0.05）,and serum HBV DNA negativity rate was 100.0%,also no significantly different as compared to 90.0% in the control（P>0.05）;at the end of 12 w and 24 w,the SBP occurred in 5（8.3%） and in 2（3.3%）,significantly lower than in 10（16.7%） and in 8（13.3% in the control （P<0.05）;at the end of 24 w,3（5%） died in the combination group,much lower than 10（16.7%） in the control（P<0.05）. Conclusion Entecavir combined with live bifidobacterium and lactobacillus tablets has a good clinical efficacy in treatment of hepatitis B patients with decompensated liver cirrhosis,which is worth further investigation.

Key words: Liver cirrhosis, Hepatitis B, Entecavir, Live bifidobacterium and lactobacillus tablets, Therapy

李波, 邓存良. 恩替卡韦联合双歧杆菌乳杆菌三联活菌片治疗失代偿期乙型肝炎肝硬化临床疗效观察[J]. 实用肝脏病杂志, 2018, 21(5): 669-672.

Li Bo, Deng Cunliang. Clinical efficacy of entecavir combined with live bifidobacterium and lactobacillus tablets in the treatment of hepatitis B patients with decompensated liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 669-672.

参考文献

[1] Luvisa BK,Hassanein TI.Hepatitis B virus infection and liver decompensation. Clin Liver Dis,2016,20(4):681-692.
[2] Peng CY,Chien RN,Liaw YF.Hepatitis B virus-related decompensated liver cirrhosis:benefits of antiviral therapy. J Hepatol,2012,57(2):442-450.
[3] Keating GM.Entecavir:a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs,2011,71(18):2511-2519.
[4] Fukui H.Gut microbiota and host reaction in liver diseases. Microorganisms,2015,3(4):759-791.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[6] Wong GL,Chan HL,Mak CW,et al.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology,2013,58(5):1537-1547.
[7] Woo HY,Choi JY,Yoon SK,et al.Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. Clin Mol Hepatol,2014,20(2):168.
[8] 傅青春,陈成伟. 重视失代偿乙型肝炎肝硬化的抗病毒治疗. 中华医学杂志,2010,90(23):1585-1586.
[9] Su TH,Hu TH,Chen CY,Huang YH,et al.Four-year entecavir therapy reduces hepatocellular carcinoma,cirrhotic events and mortality in chronic hepatitis B patients. Liver Int,2016,36(12):1755-1764.
[10] Seto WK,Hui AJ,Wong VW,et al.Treatment cessation of entecavir in Asian patients with hepatitis Be antigen negative chronic hepatitis B: a multicentre prospective study. Gut,2015,64(4):667-672.
[11] 郭立杰,王艳,王敏,等. 国产恩替卡韦治疗慢性乙型肝炎患者早期抗病毒疗效观察. 实用肝脏病杂志,2017,20(2):226-227.
[12] Kim SS,Hwang JC,Lim SG,et al.Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients:comparison between compensa-
ted and decompensated cirrhosis.Am J Gastroenterol,2014,109(8):1223-1233.
[13] Yang SC,Lee CM,Hu TH,et al.Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother,2013,68(9):2154-2163.
[14] Papatheodoridis GV,Manolakopoulos S,Touloumi G,et al.Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir:HepNet. Greece cohort. J Viral Hepat,2015,22(2):120-127.
[15] Fuller R,Perdigón G,Fuller R,et al.Gut flora,nutrition,immunity and health. Gut Flora Nut Immun Heal,2014,17(2):238-238.
[16] Goto Y,Kiyono H.Epithelial barrier:an interface for the cross-
communication between gut flora and immune system. Immunol Rev,2012,245(1):147.
[17] Lee J,Yoo SH,Sohn W,et al.Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B. Clin Mol Hepatol,2016,22(3):339-349.
[18] 何伟锋,谭斌. 恩替卡韦联合益生菌治疗失代偿期乙肝肝硬化疗效观察. 亚太传统医药,2013,9(6):153-154.
[19] 王宝根,王志军. 调节肠道菌群对乙型肝炎失代偿期肝硬化患者肝功能及腹水的影响. 中国肝脏病杂志(电子版),2014,6(4):75-76.
[20] EMiquel M,Núnezo,Trapero-Marugán M,et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.Ann Hepatol,2013,12(2):205-212.
[21] Marengo A,Bitetto D,D'Avolio A,et al. Clinical and virological response to entecavir in HBV-related chronic hepatitis or cirrhosis:data from the clinical practice in a single-centre cohort.Antivir Ther,2013,18(1):87-94.
[22] Yang H,Liu A,Zhang M,et al.Oral administration of live Bifidobacterium substrains isolated from centenarians enhances intestinal function in mice. Curr Microbiol,2009,59(4):439-445.
[23] 陈萌萌,郑吉顺,刘艳艳,等. 慢性乙型肝炎以及肝硬化患者肠道微生物研究. 安徽医科大学学报,2015,50(5):648-652.
[24] 马洪第,廉哲雄. 肠道微环境与肝脏疾病. 中国免疫学杂志,2015,31(8):1019-1013.
[25] 白宇,胡云霞,陈俊伟,等. 细菌-脑-肠轴理论体系的建立. 东南大学学报(医学版),2016,35(5):781-785.